AP NEWS

Human Growth Hormone Markets: Worldwide Outlook (2018-2022) with Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk and Pfizer Leading - ResearchAndMarkets.com

January 8, 2019

DUBLIN--(BUSINESS WIRE)--Jan 8, 2019--The “Global Human Growth Hormone Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The human growth hormone market will register a CAGR of almost 4% by 2022.

Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more.

Strong pipeline of human growth hormone

Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.

Poor patient adherence

The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.

Key Players

Eli Lilly F. Hoffmann-La Roche Novo Nordisk Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY DRUG TYPE

PART 09: MARKET SEGMENTATION BY APPLICATION

Segmentation by application Comparison by application Growth hormone deficiency - Market size and forecast 2017-2022 ISS - Market size and forecast 2017-2022 Turner syndrome - Market size and forecast 2017-2022 PWS - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

Increasing incidence of growth disorders No impact of biosimilar entry into market Advanced technologies

PART 15: VENDOR LANDSCAPE

Overview Landscape disruption

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Eli Lilly F. Hoffmann-La Roche Novo Nordisk Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/mm9bj4/human_growth?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190108005743/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/08/2019 10:36 AM/DISC: 01/08/2019 10:36 AM

http://www.businesswire.com/news/home/20190108005743/en

AP RADIO
Update hourly